18F-FLT PET Studies in Patients with Breast Cancer
| No. of patients | Study aim(s) | Results | Reference |
| 18 | Determine whether early changes in 18F-FLT PET can predict benefit from docetaxel | Docetaxel decreased 18F-FLT uptake; early reduction in tumor SUV correlated with tumor size changes after 3 cycles and predicted midtherapy response | 58 |
| 13 | Define objective criteria for 18F-FLT response and examine whether 18F-FLT PET can be used to quantify early response of stage II–IV breast cancer to FEC | Clinical response at day 60 was related to reduction in 18F-FLT uptake at 1 wk; decreases in Ki-67 and SUV90 at 1 wk discriminated between clinical response and stable disease | 59 |
| 15 | Evaluate whether 18F-FLT PET can predict final postoperative histopathologic response in primary locally advanced breast cancer after 1 cycle of NAC | Potential utility for early monitoring of response | 60 |
| 28 | Investigate diagnostic performance of 18F-FLT PET in women with suspect breast findings on conventional imaging | SUV of malignant lesions was higher than that of benign lesions | 61 |
| 30 | Investigate quantitative methods of tumor proliferation with 18F-FLT PET before and after single bevacizumab administration and correlate 18F-FLT uptake with Ki-67 | 18F-FLT uptake decreased after treatment | 62 |
| 20 | Assess feasibility of 18F-FLT PET/CT for predicting response to NAC and for comparing baseline 18F-FLT with Ki-67 | No association of baseline, postchemotherapy, or change in SUVmax with pathologic response to NAC; prechemotherapy Ki-67 correlated with SUVmax | 63 |
| 15 | Validate approach to quantify 18F-FLT PET data in stage II–IV breast cancer patients and study whether 18F-FLT PET can predict early treatment response | Differences before and after therapy in mean voxel uptake in tumor did not allow complete responder/nonresponder classification | 64 |
| 12 | Evaluate use of 18F-FLT PET for diagnosis of breast cancer | Totals of 13/14 primary tumors and 7/8 histologically proven lymph node metastases showed uptake | 65 |
| 14 | Examine side-by-side 18F-FDG imaging and 18F-FLT imaging for monitoring and predicting chemotherapy response | Mean change in 18F-FLT uptake correlated with late changes in CA27.29 and CT response | 66 |
| 10 | Study feasibility of 18F-FLT PET for breast cancer visualization | Totals of 8/10 primary tumors and 2/7 axillary lymph node metastases showed uptake | 67 |
FEC = 5-fluorouracil–epirubicin–cyclophosphamide; Ki-67 = cellular marker for proliferation; NAC = neoadjuvant chemotherapy.